FOLLOWING the death of one person last month from a suspected fatal reaction to the andrographis medicine, Armaforce, the TGA is reconsidering whether the current labelling is sufficient to address safety concerns.
Reported reactions included anaphylaxis, seizure, swelling, nausea, throat tightness and dizziness, and patients are being asked to stop using andrographis medicines at the first sign of an allergic reaction.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jul 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jul 24
